Dendreon completes Provenge BLA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Nov. 9 electronic submission of the chemistry, manufacturing and controls section of the application completes Dendreon's rolling BLA for the active cellular immunotherapy Provenge (sipuleucel-T). The company is requesting a priority review for the BLA, which seeks an indication for asymptomatic, metastatic hormone-refractory (androgen-independent) prostate cancer. Dendreon initiated the rolling BLA in August (1Pharmaceutical Approvals Monthly September 2006, p. 28)...
You may also be interested in...
Therapeutic Vaccine Trials Should Focus More On Patient Response – Study
A paradigm shift is needed in the field of therapeutic cancer vaccine trials that would evaluate patient response rather than tumor response, according to an analysis of prostate cancer vaccine trials in the July 1 issue of Clinical Cancer Research.
Dendreon Provenge BLA gets rolling
Dendreon expects to complete its rolling BLA for its prostate cancer vaccine Provenge (sipuleucel-T) "later this year," the firm announces Aug. 24. The biotech initiated a rolling BLA for metastatic, hormone-refractory prostate cancer with the submission of the clinical and non-clinical portions of the package, leaving the chemistry, manufacturing and controls section to be submitted later in 2007...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.